Survival analyses of the subgroup of serous ovarian cancers revealed a trend toward longer PFS for ovarian cancer patients whose tumors showed low expression of ERRγ compared to those with medium and high expression (data not shown). The gene discussed is ESRRG; the disease is ovarian serous adenocarcinoma.